Clene Q3 net loss narrows to $2.4M; ALS drug shows survival benefit, receives $45.1M NIH grant

Clene Inc.

Net loss $2.4M ($0.02/sh) vs $11.0M ($0.17/sh) in Q3 2022; R&D expense $6.0M.
Cash $42.1M as of Sep 30, 2023, expected to fund operations into Q3 2024.
CNM-Au8 in ALS: 19.3-month median survival benefit in RESCUE-ALS OLE; 49% decreased death risk in HEALEY vs PRO-ACT historical controls.
Awarded $45.1M NINDS/NIH grant for expanded access of CNM-Au8 in ALS.
FDA regulatory discussion planned for Q4 2023 to accelerate ALS submission path.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Clene Inc. reported third quarter 2023 results: net income $2.4 million, EPS $0.02 per share.

Period: third quarter 2023
Net income: $2.4 million
EPS: $0.02 per share
Result: reported results

Exact text from the filing

Clene reported a net loss of $2.4 million, or $0.02 per share, for the quarter ended September 30, 2023

View on SEC.gov

Browse all earnings releases →

Clene Inc. filing history →

Source: SEC EDGAR

accession 0001437749-23-030493

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.